Apocynin is a selective NADPH-oxidase inhibitor with IC50 of 10 μM. apocynin is an intracellular inhibitor of the assembly of NADPH oxidase in neutrophils and eosinophils and that apocynin requires conversion by peroxidases to exert its inhibitory effec [1] Apocynin can decrease the production of superoxide (O(2)(-)) from activated neutrophils and macrophages. Apocynin, after metabolic conversion, inhibits the assembly of NADPH-oxidase that is responsible for reactive oxygen species (ROS) production.[2] NADPH-oxidase is an enzyme responsible for reactive oxygen species production (ROS) and inhibition of this enzyme represents an attractive therapeutic target for the treatment of many diseases. [3]
Clinical Trial
NCT Number
Sponsor
Condition
Start Date
Phase
NCT00992667
Medical Universtity of Lodz|Ministry of Science and Higher Education, Poland
Bronchial Asthma
June 2008
Phase 1
NCT01402297
Medical Universtity of Lodz|Ministry of Science and Higher Education, Poland